Exeliom to focus on gastric cancer landscape with immune modulating drug
Exeliom is running three Phase II trials of the candidate in three oncology indications but will focus on the gastric cancer approval route.
Exeliom is running three Phase II trials of the candidate in three oncology indications but will focus on the gastric cancer approval route.